Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement

IntroductionTreatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows poor response rates in non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) patients with multiple extranodal involvement. This study aims to evaluate anti-tumor...

Full description

Bibliographic Details
Main Authors: Hongzhi Geng, Sixun Jia, Ying Zhang, Jiaqi Li, Qin Yang, Liangyu Zeng, Xiangping Zong, Yutong Lu, Shuangzhu Lu, Jin Zhou, Caixia Li, Depei Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
zanubrutinib
untreated non-GCB DLBCL
extranodal involvement
anti-tumor activity
oncogenic mutations
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219167/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219167/full

Similar Items